SIETES :: 92082 citas

Resultados de la búsqueda por PSIQUIATRÍA REFINAR BÚSQUEDA

1.

Alshehri GH, Keers RN, Ashcroft DM. Frequency and nature of medication errors and adverse drug events in mental health hospitals: a systematic review. Drug Saf 2017;40:871-86. [Ref.ID 102076]

2.

Anónimo. Antidépresseurs IRS et grossesse: autisme?. Prescrire 2017;37:428-9. [Ref.ID 102002]

3.

Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]

4.

Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]

5.

Rai D, Lee BK, Dalman C, Newschaffer C, Lewis G, Magnusson C. Antidepressants during pregnancy and autism in offspring: population based cohort study. BMJ 2017;358:j2811. [Ref.ID 101979]

6.

Obach M, Lopez P, Catalan A. Tratamiento farmacológico de la enfermedad de Alzheimer en la población de Catalu˜na. Med Clin (Barc) 2017;149:86-7. [Ref.ID 101905]

7.

Anónimo. Guanfacine et déficit de l'attention avec hyperactivité. Prescrire 2017;37:329-32. [Ref.ID 101647]

8.

Mezzacappa A, Lasica P-A, Gianfagna F. Risk of autism spectrum disorders according to period of prenatal antidepressant exposure. A systematic review and meta-analysis. JAMA Pediatrics 2017;171:555-63. [Ref.ID 101641]

9.

Patorno E, Huybrechts KF, Bateman BT, Cohen JM, Desai RJ, Mogun H, Cohen LS, Hernández-Díaz S. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med 2017;376:2245-54. [Ref.ID 101629]

10.

Man KKC, Chan EW, Ip P, Coghill D, Simonoff E, Chan PKL, Lau WCY, Schuemie MJ, Sturkenboom MCJM, Wong ICK. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ 2017;357:j2350. [Ref.ID 101616]

11.

Anónimo. Tratamiento de la depresión en atención primaria: cuándo y con qué. Infac: Información Farmacoterapéutica de la Comarca 2017;25:1-11. [Ref.ID 101542]

12.

Anónimo. Malformations congénitales chez les enfants exposés in utero au valproate et aux autres traitements de l’épilepsie et des troubles bipolaires - Communiqué. Agence nationale de securité du médicament et des produits de santé 2017:20 de abril. [Ref.ID 101537]

13.

Biffi A, Scotti L, Corrao G. Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies. Eur J Clin Pharmacol 2017;73:487-97. [Ref.ID 101517]

14.

Soyka M. Treatment of benzodiazepine dependence. N Engl J Med 2017;376:1147-57. [Ref.ID 101503]

15.

Németh G, Laszlovsky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy A, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet 2017;389:1103-13. [Ref.ID 101497]

16.

Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescriptions opioids. JAMA 2017;317:967-8. [Ref.ID 101470]

17.

Wong J, Motulski A, Abrahamowicz M, McGill J, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 2017;356:j603. [Ref.ID 101417]

18.

Morales DR, Guthrie B. Off-label prescribing of antidepressants. BMJ 2017;356:j849. [Ref.ID 101416]

19.

Maust DT, Gerlach LB, Gibson A, Kales HC, Blow FC, Olfson M. Trends in central nervous system – Active polypharmacy among older adults seen in outpatient care in the United States. JAMA Intern Med 2017;177:583-5. [Ref.ID 101408]

20.

Agar MR, Lawlor PG, Quinn S, Draper B, Caplan GA, Rowett D, Sanderson C, Hardy J, Le B, Eckermann S, McCaffrey N, Devilee L, Fazekas B, Hill M, Currow DC. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med 2017;177:34-42. [Ref.ID 101343]